The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 08, 1996

Filed:

May. 13, 1994
Applicant:
Inventors:

Mark D Hylarides, Snohomish County, WA (US);

Ananthachari Srinivasan, King County, WA (US);

Jeffrey N Fitzner, King County, WA (US);

Vivekananda M Vrudhula, Snohomish County, WA (US);

Assignee:

NeoRx Corporation, Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H / ; C07H / ; C07H / ; C07D / ; C07D / ; C07D / ; C07D / ; C07D / ;
U.S. Cl.
CPC ...
536-41 ; 536-6 ; 536-61 ; 536-62 ; 536 172 ; 536 173 ; 536 175 ; 536 182 ; 536 183 ; 536 184 ; 536 187 ; 536 221 ; 536 53 ; 536 54 ; 536115 ; 536122 ; 546243 ; 546244 ; 546246 ; 546248 ; 548543 ; 548550 ; 548551 ; 548558 ; 549 28 ; 549 62 ; 549 65 ; 549 68 ; 549 72 ; 549 73 ; 549416 ; 549417 ; 549419 ; 549476 ; 549480 ; 549491 ; 549497 ;
Abstract

The present invention provides cleavable conjugates whose linkers contain a labile bond that is cleavable under a variety of mild conditions, including weakly acidic. Since the agent may be bonded directly to the linker, cleavage can result in release of native agent. The invention also provides methods for producing cleavable conjugates. Preferred agents include drugs, toxins, biological response modifiers, radiodiagnostic compounds, radiotherapeutic compounds, and derivatives thereof. The targeting molecule employed in the invention may be an intact molecule, a fragment thereof, or a functional equivalent thereof. In a particularly preferred embodiment, the targeting molecule is a monoclonal antibody directed towards a tumor-associated antigen in man. The invention further provides methods for delivering to the cytoplasm of a target cell an agent free of its targeting molecule carrier. A diagnostically/therapeutically effective dose of a cleavable conjugate is administered to a warm-blooded animal such as man.


Find Patent Forward Citations

Loading…